WORLD HEALTH ORGANIZATION

The Healthcare Contract Research Outsourcing Market is projected to grow from USD 50.8 billion in 2023 to USD 100.9 billion by 2033, driven by increased R&D investment, patent expirations, and government partnerships. Rising funding for pharmaceutical and biotech firms, globalization of clinical trials, and specialized CRO services are key factors. CROs offer diverse services, including clinical trial management, regulatory compliance, and data analysis, supporting rapid drug development and market entry. Emerging trends include real-world evidence, advanced drug pricing models, and AI in healthcare, enhancing efficiency and patient-centric care.

The ATTENTION trial in Korea and Taiwan showed Vemlidy (tenofovir alafenamide) significantly reduced liver-related events in non-cirrhotic hepatitis B patients with normal ALT levels, emphasizing early treatment's importance to prevent HCC and reduce healthcare costs.

The 2024 Beijing Capital International Medical Conference, part of the 2024 China International Fair for Trade in Services, emphasized health as a national priority, focusing on optimizing health services, advancing medical innovation, and enhancing international cooperation. The event featured discussions on disease prevention, AI in healthcare, and health technology, aiming to promote global health and high-quality development in medical services.

CDC reports cautious optimism as STI epidemic in the US shows signs of slowing, with decreases in gonorrhea and syphilis cases. However, over 2.4 million STIs were reported in 2023. Chlamydia remains the most common, with adolescents and young adults most affected. Increased testing, treatment, and public health funding are key to controlling the epidemic.

The WHO defines medical devices broadly, with over 2 million types globally. The FDA regulates these, including AI-driven tools, amidst cybersecurity vulnerabilities. Over half of internet-connected devices in hospitals have critical vulnerabilities. The FDA plans to issue guidance on cybersecurity and AI, seeking industry feedback to enhance safety and security.

AbbVie's emraclidine did not reduce PANSS scores in Phase II EMPOWER trial, prompting further data analysis. Despite unmet primary endpoint, a tolerable safety profile was observed. Schizophrenia affects 24 million globally, with significant under-treatment.

The whole genome sequencing market is projected to reach $7.17 billion by 2031 at a CAGR of 15.2%. Factors driving growth include declining sequencing costs, increasing cancer & genetic disorder prevalence, and advancements in precision medicine. Key players include Illumina, Thermo Fisher Scientific, QIAGEN, and F. Hoffmann-La Roche.

Recce Pharmaceuticals receives ethics approval for Phase 3 trial of RECCE®327 Topical Gel for Diabetic Foot Infections in Indonesia, with expected read-out in late 2025 and commercial launch in H1 2026, supported by Australian and Indonesian governments.

The 7th Apollo Cancer Conclave, attended by over 2,000 oncologists, focused on latest advances in cancer care, from contemporary treatments to precision oncology. Held from November 8th to 10th, it featured 7 organ-specific tracks, over 100 sessions, and interactive discussions. Key speakers included Dr. Elisabete Weiderpass, Ms. Preetha Reddy, Mr. Dinesh Madhavan, and Dr. Anil D’cruz, emphasizing prevention, innovative treatments, and patient-centric care. The event also introduced new Breast Cancer Care guidelines and showcased advancements in precision oncology, robotics, AI, and clinical collaboration.

Systematic review confirms lifelong immunity from a single yellow fever vaccine, with rare cases of breakthrough infections, supporting WHO's stance on no need for booster doses.